bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
bioAffinity Technologies (Nasdaq: BIAF) has been granted a patent in Japan for its CyPath® Lung diagnostic test method, which predicts lung cancer likelihood. This marks the first patent specifically for CyPath® Lung as a standalone flow cytometry test for lung cancer detection. The patent, titled 'System and Method for Determining the State of Health of the Lungs,' adds to the company's portfolio of 17 awarded patents and 30 pending applications across various regions. The company focuses on developing noninvasive tests for early-stage lung cancer and other lung diseases detection.
bioAffinity Technologies (Nasdaq: BIAF) ha ricevuto un brevetto in Giappone per il suo metodo di test diagnostico CyPath® Lung, che prevede la probabilità di cancro ai polmoni. Questo rappresenta il primo brevetto specifico per CyPath® Lung come test di citometria a flusso autonomo per la rilevazione del cancro ai polmoni. Il brevetto, intitolato 'Sistema e Metodo per Determinare lo Stato di Salute dei Polmoni', si aggiunge al portafoglio dell'azienda di 17 brevetti concessi e 30 domande pendenti in varie regioni. L'azienda si concentra sullo sviluppo di test non invasivi per la rilevazione precoce del cancro ai polmoni e di altre malattie polmonari.
bioAffinity Technologies (Nasdaq: BIAF) ha recibido una patente en Japón para su método de prueba diagnóstico CyPath® Lung, que predice la probabilidad de cáncer de pulmón. Este es el primer patente específicamente para CyPath® Lung como una prueba de citometría de flujo independiente para la detección del cáncer de pulmón. La patente, titulada 'Sistema y Método para Determinar el Estado de Salud de los Pulmones', se suma al portafolio de la compañía de 17 patentes otorgadas y 30 solicitudes pendientes en varias regiones. La empresa se centra en desarrollar pruebas no invasivas para la detección de cáncer de pulmón en etapas tempranas y otras enfermedades pulmonares.
bioAffinity Technologies (Nasdaq: BIAF)는 일본에서 CyPath® Lung 진단 테스트 방법에 대한 특허를 받았으며, 이는 폐암 가능성을 예측합니다. 이는 폐암 탐지를 위한 독립적인 유세포 분석 테스트로서 CyPath® Lung에 대한 첫 번째 특허입니다. '폐의 건강 상태를 결정하는 시스템 및 방법'이라는 제목의 이 특허는 다양한 지역에서 17개의 특허를 소유하고 30개의 신청이 대기 중인 회사의 포트폴리오에 추가됩니다. 이 회사는 조기 폐암 및 기타 폐 질환 탐지를 위한 비침습적 테스트 개발에 집중하고 있습니다.
bioAffinity Technologies (Nasdaq: BIAF) a obtenu un brevet au Japon pour sa méthode de test diagnostique CyPath® Lung, qui prédit la probabilité d'un cancer du poumon. Cela marque le premier brevet spécifiquement pour CyPath® Lung en tant que test de cytométrie en flux autonome pour la détection du cancer du poumon. Le brevet, intitulé 'Système et Méthode pour Déterminer l'État de Santé des Poumons', s'ajoute au portefeuille de l'entreprise de 17 brevets accordés et 30 demandes en attente dans diverses régions. L'entreprise se concentre sur le développement de tests non invasifs pour la détection précoce du cancer du poumon et d'autres maladies pulmonaires.
bioAffinity Technologies (Nasdaq: BIAF) hat in Japan ein Patent für sein diagnostisches Testverfahren CyPath® Lung erhalten, das die Wahrscheinlichkeit von Lungenkrebs vorhersagt. Dies ist das erste Patent, das speziell für CyPath® Lung als eigenständigen Durchflusszytometrietest zur Erkennung von Lungenkrebs vergeben wurde. Das Patent mit dem Titel 'System und Methode zur Bestimmung des Gesundheitszustands der Lungen' erweitert das Portfolio des Unternehmens auf 17 erteilte Patente und 30 ausstehende Anträge in verschiedenen Regionen. Das Unternehmen konzentriert sich auf die Entwicklung von nicht-invasiven Tests zur frühzeitigen Erkennung von Lungenkrebs und anderen Lungenerkrankungen.
- Secured new Japanese patent for CyPath® Lung diagnostic test
- First patent specifically for CyPath® Lung as standalone lung cancer detection test
- Strong IP portfolio with 17 awarded patents and 30 pending applications
- None.
The Japanese patent, titled “System and Method for Determining the State of Health of the Lungs,” is an important addition to bioAffinity Technologies’ patent portfolio, which includes 17 awarded
“The Japanese patent for CyPath® Lung is a significant step forward in extending protection for the intellectual property behind our innovative, noninvasive test for early-stage lung cancer. We anticipate patents in additional geographic regions will follow,” bioAffinity Technologies President and CEO Maria Zannes said. “Lung cancer is the deadliest cancer worldwide. We believe CyPath® Lung has the potential to improve the outcome for lung cancer patients around the globe through earlier detection when treatment options are better. Strong intellectual property protection for CyPath® Lung benefits not only patients and their physicians, but also our shareholders and our Company. Our scientific team continues research and development on diagnostics that will open new markets for bioAffinity Technologies.”
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding patents in additional geographic regions following the Japanese patent, improving the outcome for lung cancer patients around the world through earlier detection when treatment options are better, strong intellectual property protection benefitting patients, their physicians, the Company and the Company’s shareholders, and the Company’s scientific team continuing research and development on diagnostics that will open new markets for the Company. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to protect its intellectual property with both
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030599304/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.
FAQ
What patent did bioAffinity Technologies (BIAF) receive in Japan?
How many patents does bioAffinity Technologies (BIAF) currently hold?
What is significant about the Japanese patent for bioAffinity Technologies' (BIAF) CyPath® Lung?
